# Prevalence of PD-L1 Expression in Patients With Advanced Urothelial Carcinoma

> **NCT03788746** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 181 (actual)

## Conditions studied

- Urothelial Carcinoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03788746
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-17
- **Primary completion:** 2022-01-12
- **Final completion:** 2023-05-25
- **Target enrollment:** 181 (ACTUAL)
- **Last updated:** 2024-02-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03788746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03788746, "Prevalence of PD-L1 Expression in Patients With Advanced Urothelial Carcinoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03788746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*